Biogen Inc. DL-Notes 2020(20/30)
- BID
90.525
- ASK
90.751
- 324,000 Nom.500,000 Nom.
- 07/27, 21:08:36 PM
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
5.12
Yield spread Bundesanleihe
2.2809
Tradable for private investors
No
Minimum amount tradeable unit
2,000.00
Maturity
01/05/2030
Interest Rate
2.25 %
Currency
US Dollar
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE / YIELD | 90.542 G / 5.12 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 09:02:05 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 2.2809 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 90.62 | 90.5 |
| PREV. DAY'S PRICE | 90.444 | (07/24) |
| CHANGE DAY BEFORE | +0.10 | 0.11 % |
| 52 WEEK HIGH / LOW | 92.743 (02/27) | 89.29 (08/01) |
Master Data
| WKN | A28WVM |
| ISIN | US09062XAH61 |
| SYMBOL | IDPE |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | Biogen Inc. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 2.25 % |
| INTEREST RUN FROM | 30/04/2020 |
| NEXT INTEREST PAYMENT | 31/10/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 0.556 % |
| TRADING CURRENCY / NOTATION | US Dollar/ Percent |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 1.50 Bil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 2,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 01/05/2030 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Local currency bond: USD. Make Whole Call Option. Callable bond.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.